Drug Trial Radar · NCT07291284
Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis
Last checked: Nov 19, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
546
Actual
Start
Aug 1, 2024
Primary completion
Mar 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Dec 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of LP-003 injection in patients with moderate to severe seasonal allergic rhinitis inadequately controlled by standard-of-care.
Conditions
- Seasonal Allergic Rhinitis
Interventions
LP-003Biological
Participants were administered LP-003 via subcutaneous injection every 4 weeks.
PlaceboBiological
Participants were administered Placebo via subcutaneous injection every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean daily reflective total nasal symptom score (rTNSS) during the pollen peak period (PPP)Time frame: Up to 4 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Shijitan Hospital, Capital Medical University (the formerly Beijing Railway General Hospital)
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.